NCT04513626View on ClinicalTrials.gov

HIV-1 Infected Patients, Phase II Trial, Dual Combination Doravirine/Raltegravir Open Label

PHASE2RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

September 15, 2020

Primary Completion Date

October 30, 2025

Study Completion Date

October 30, 2025

Conditions
HIV Infections
Interventions
DRUG

DORAVIRINE 100 MG [Pifeltro]

Immediate switch

Trial Locations (1)

75013

RECRUITING

Christine KATLAMA, Paris

All Listed Sponsors
lead

Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida

OTHER